Literature DB >> 35113204

[Axial spondyloarthritis : Update on management based on the interdisciplinary S3 guidelines on axial spondyloarthritis including early forms and ankylosing spondylitis].

D Kiefer1, J Braun1, U Kiltz2.   

Abstract

This review article presents the innovations in the update of the S3 guidelines on axial spondylarthritis. The total of eight new recommendations address the areas of the consideration of differential diagnoses, coordination of comorbidity management, including a vaccination strategy, treatment targets, safety of nonsteroidal anti-inflammatory drugs (NSAID), treatment response to biological disease-modifying antirheumatic drugs (bDMARD) and discontinuation strategies when remission has been achieved. In this article the authors deal particularly with the areas of early diagnosis and referral as well as exercise therapy and drug treatment.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Differential diagnosis; Drug treatment; Early diagnosis; Exercise therapy; Referral

Mesh:

Substances:

Year:  2022        PMID: 35113204     DOI: 10.1007/s00393-021-01147-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  3 in total

1.  Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis.

Authors:  Zhixiu Li; Xin Wu; Huji Xu; Matthew A Brown; Paul J Leo; Erika De Guzman; Nurullah Akkoc; Maxime Breban; Gary J Macfarlane; Mahdi Mahmoudi; Helena Marzo-Ortega; Lisa K Anderson; Lawrie Wheeler; Chung-Tei Chou; Andrew A Harrison; Simon Stebbings; Gareth T Jones; So-Young Bang; Geng Wang; Ahmadreza Jamshidi; Elham Farhadi; Jing Song; Li Lin; Mengmeng Li; James Cheng-Chung Wei; Nicholas G Martin; Margaret J Wright; MinJae Lee; Yuqin Wang; Jian Zhan; Jin-San Zhang; Xiaobing Wang; Zi-Bing Jin; Michael H Weisman; Lianne S Gensler; Michael M Ward; Mohammad Hossein Rahbar; Laura Diekman; Tae-Hwan Kim; John D Reveille; Bryan Paul Wordsworth
Journal:  Ann Rheum Dis       Date:  2021-04-20       Impact factor: 19.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.